Autres langues Cyclo Therapeutics, Inc.

Actions

CYTH

US23254X2018

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 27/06/2024			Varia. 5j.	Varia. 1 janv.
1,2 ^USD	-1,64 %		0,00 %	-24,53 %

30/05	Cyclo Therapeutics, Inc. franchit une étape importante avec la fin du recrutement du dernier patient dans l'étude pivot de phase 3 sur le traitement de la maladie de Niemann-Pick de type C1 (TransportNPC).	CI
24/05	Cyclo Therapeutics dépose une déclaration d'enregistrement mixte de 100 millions de dollars	MT

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024	26/06
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024	25/06
Cyclo Therapeutics, Inc. announced that it has received $2 million in funding from Rafael Holdings, Inc.	11/06
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1	31/05
Cyclo Therapeutics, Inc. Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1	30/05
Cyclo Therapeutics Files $100 Million Mixed Shelf	24/05
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	16/05
Cyclo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Cyclo Therapeutics : Corporate Presentation	02/05
Cyclo Therapeutics : Corporate Presentation	18/04
Cyclo Therapeutics : Corporate Presentation	18/03
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update	18/03
Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol Cyclo for the Treatment of Alzheimer's Disease	15/03
Cyclo Therapeutics Granted Patent Covering Use of Trappsol Cyclo for Alzheimer's Disease	14/03
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease	14/03
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office	30/01
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office	29/01
Cyclo Therapeutics : Modification to Rights of Security Holders - Form 8-K	28/12
Cyclo Therapeutics, Applied Molecular Transport Complete Merger	27/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Cyclo Therapeutics, Inc.

Actions

CYTH

US23254X2018

Autres langues

Filtres